Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Buthiazide is a thiazide diuretic used primarily for the treatment of hypertension (high blood pressure) and edema. Thiazides act on the distal convoluted tubule of the nephron in the kidney to inhibit the sodium-chloride symporter (solute carrier family 12 member 3), thereby reducing sodium reabsorption and increasing excretion of sodium and water in urine. This leads to decreased extracellular fluid volume and lower blood pressure. Buthiazide shares its mechanism with other thiazides such as hydrochlorothiazide and chlorothiazide. The class was originally developed by Merck in the 1950s[5][1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on buthiazide.